Kyowa Kirin Co., Ltd. (KYKOF)
| Previous close | 22.90 |
| Open | 22.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 22.90 - 22.90 |
| 52-week range | 21.22 - 36.25 |
| Volume | |
| Avg. volume | 846 |
| Market cap | 12.301B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 33.38 |
| EPS (TTM) | 0.69 |
| Earnings date | N/A |
| Forward dividend & yield | 0.42 (1.77%) |
| Ex-dividend date | 29 Dec 2022 |
| 1y target est | N/A |
- Business Wire
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
SAN DIEGO & TOKYO, July 18, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor, in
- Business Wire
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
SAN DIEGO & TOKYO, June 10, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered
- Business Wire
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
SAN DIEGO & TOKYO, June 04, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta
